The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathologic characteristics of HRAS-mutant head and neck squamous cell carcinoma (HNSCC).
 
Coral Olazagasti
No Relationships to Disclose
 
Estelamari Rodriguez
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Janssen Oncology; Novartis; Oncocyte; Research to Practice
 
Asaad Trabolsi
No Relationships to Disclose
 
Samuel Kareff
No Relationships to Disclose
 
Jun Yin
No Relationships to Disclose
 
Phillip Walker
Employment - Caris Life Sciences
 
Trisha Michel Wise-Draper
Stock and Other Ownership Interests - High Enroll
Honoraria - Physicans' Education Resource
Consulting or Advisory Role - Caris Life Sciences; Exicure; Merck; Rakuten Medical; Shattuck Labs
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; GlaxoSmithKline; Janssen Oncology; Merck
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; bexion; Bristol-Myers Squibb; Caris Life Sciences; Caris Life Sciences; Lilly; Merck; Tesaro
 
Rebecca Chernock
Research Funding - Caris Life Sciences
Travel, Accommodations, Expenses - Roche
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Caris Life Sciences
 
Glenn J. Hanna
Honoraria - Bristol-Myers Squibb; Kura Oncology
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Exicure; General Catalyst; Kura Oncology; Merck; Naveris; Prelude Therapeutics; Rain Therapeutics; Remix Therapeutics; Sanofi
Research Funding - Actuate Therapeutics (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); Secura Bio (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch; Ahmuty, Demers, & McManus; Wilson Elser Moskowitz Edelman & Dicker, LLP
 
David Spetzler
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Caris Life Sciences
Research Funding - Caris Life Sciences
Patents, Royalties, Other Intellectual Property - Caris Life Sciences holds and has pending patents with intellectual property interests relating to health and medicine.
Travel, Accommodations, Expenses - Caris Life Sciences
 
Gilberto Lopes
Stock and Other Ownership Interests - Lucence Diagnostics; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Merck
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
Other Relationship - Mirati Therapeutics